Clinical trial
Phase I Study of Afatinib With Postoperative Radiation Therapy for Intermediate and High Risk Squamous Cancer of the Head and Neck (SCCHN)
NCT01783587 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I Study of Afatinib With Postoperative Radiation Therapy for Intermediate and High Risk Squamous Cancer of the Head and Neck (SCCHN)
- Lead sponsor
- Dana-Farber Cancer Institute
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- February 28, 2013
- Completion date
- June 1, 2018
- Enrollment
- 29 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
squamous cell carcinoma of the head and neck